THE GROUNDS OF CLARITROMYCIN USE IN THE TREATMENT OF PSORIASIS

Abstract. Claritromycin influence on the keratinocytes proliferation and differentiation and lymphocytes proliferation and clasters of differentiation expression in vitro was investigated. It was established that claritromycin in dose 2 mkg/ml inhibited psoriatic keratinocytes proliferation and incr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	V. L. Rybkina
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	psoriasis treatment claritromycin keratinocytes lymphocytes Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/4f954af23b7940bcb3becb04bc612d13
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f954af23b7940bcb3becb04bc612d13
record_format	dspace
spelling	oai:doaj.org-article:4f954af23b7940bcb3becb04bc612d132021-11-18T08:03:41ZTHE GROUNDS OF CLARITROMYCIN USE IN THE TREATMENT OF PSORIASIS1563-06252313-741X10.15789/1563-0625-2005-4-405-410https://doaj.org/article/4f954af23b7940bcb3becb04bc612d132014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/495https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Claritromycin influence on the keratinocytes proliferation and differentiation and lymphocytes proliferation and clasters of differentiation expression in vitro was investigated. It was established that claritromycin in dose 2 mkg/ml inhibited psoriatic keratinocytes proliferation and increased its differentiation degree in culture. Claritromycin influence was mediated by CD4+ lymphocytes. Furthermore, claritromycin in vitro decreased the number of СD25+ lymphocytes and spontaneous and PHA-induced lymphocytes proliferation for psoriatic patients. These data allow to include claritromycin in the treatment regimen of psoriasis.V. L. RybkinaSPb RAACIarticlepsoriasistreatmentclaritromycinkeratinocyteslymphocytesImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 7, Iss 4, Pp 405-410 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	psoriasis treatment claritromycin keratinocytes lymphocytes Immunologic diseases. Allergy RC581-607
spellingShingle	psoriasis treatment claritromycin keratinocytes lymphocytes Immunologic diseases. Allergy RC581-607 V. L. Rybkina THE GROUNDS OF CLARITROMYCIN USE IN THE TREATMENT OF PSORIASIS
description	Abstract. Claritromycin influence on the keratinocytes proliferation and differentiation and lymphocytes proliferation and clasters of differentiation expression in vitro was investigated. It was established that claritromycin in dose 2 mkg/ml inhibited psoriatic keratinocytes proliferation and increased its differentiation degree in culture. Claritromycin influence was mediated by CD4+ lymphocytes. Furthermore, claritromycin in vitro decreased the number of СD25+ lymphocytes and spontaneous and PHA-induced lymphocytes proliferation for psoriatic patients. These data allow to include claritromycin in the treatment regimen of psoriasis.
format	article
author	V. L. Rybkina
author_facet	V. L. Rybkina
author_sort	V. L. Rybkina
title	THE GROUNDS OF CLARITROMYCIN USE IN THE TREATMENT OF PSORIASIS
title_short	THE GROUNDS OF CLARITROMYCIN USE IN THE TREATMENT OF PSORIASIS
title_full	THE GROUNDS OF CLARITROMYCIN USE IN THE TREATMENT OF PSORIASIS
title_fullStr	THE GROUNDS OF CLARITROMYCIN USE IN THE TREATMENT OF PSORIASIS
title_full_unstemmed	THE GROUNDS OF CLARITROMYCIN USE IN THE TREATMENT OF PSORIASIS
title_sort	grounds of claritromycin use in the treatment of psoriasis
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/4f954af23b7940bcb3becb04bc612d13
work_keys_str_mv	AT vlrybkina thegroundsofclaritromycinuseinthetreatmentofpsoriasis AT vlrybkina groundsofclaritromycinuseinthetreatmentofpsoriasis
_version_	1718422476058263552

THE GROUNDS OF CLARITROMYCIN USE IN THE TREATMENT OF PSORIASIS

Ejemplares similares